GeneDx (WGS) reported earnings on Tue 18 Feb 25 (b/o)

• Sema4 (SMFR); IPO 23 Jul 21; rebranded GeneDx (WGS)  (January 10, 2023)

** charts after earnings ** 

Strong Beat, Guidance: This provider of exome and genome tests is a play on the shift toward personalized medicine and earlier intervention.

During the fourth quarter, GeneDx earned an adjusted 77 cents per share, obliterating forecasts for 16 cents, according to FactSet. Earnings flipped from a year-earlier loss of 49 cents. Sales grew almost 65% to $95.6 million, well ahead of calls for $82.2 million.

GeneDx also guided to $350 million to $360 million in full-year sales. The low end of the outlook easily beat analysts' forecast for $340.4 million.

GeneDx uses AI to provide genomics-related diagnostic testing.

GeneDx provides whole genome and exome sequencing to help identify rare diseases, primarily in children. The genome includes all the DNA in the body, while reading the exome involves looking at only the protein-coding genes.

When performed early, genetic testing can lead to answers that help avoid what Chief Executive Katherine Stueland calls a "diagnostic odyssey." The company only tests for diseases where there is a solution — a clinical study, a dietary change or a treatment.

GeneDx (WGS) : 3-year performance

GeneDx began trading under WGS on January 10, 2023. The Company previously traded under SMFR, reflective of the company's former name, Sema4 which went public via merger with CM Life Sciences (CMLF), a special purpose acquisition company (SPAC), on July 23, 2021, at a valuation of around $3 billion.

• Sector: Healthcare
• Industry: Diagnostics & Research
• Full Time Employees: 1,000
• Founded by Eric Schadt in October 2015
• Headquartered in Stamford, Connecticut
• https://www.genedx.com/

Clinical data and genomics company 

Sema4 was spun out of Mount Sinai Health System in 2017 The Sema4 platform uses machine learning and other artificial intelligence tools to analyze a database of more than 10 million patient genomic profiles and clinical records, with the goal of improving physicians’ ability to diagnose, manage and ultimately prevent disease.